BioCentury | Jul 25, 2016
Strategy

Paving the way

...Inc. (NYSE:MRK) Mkt in EU, South Korea Hanwha Chemical Corp. (KSE:009830) Mkt in South Korea Intas...
BioCentury | May 4, 2015
Company News

Intas Pharmaceuticals sales and marketing update

...Intas launched Intacept, a biosimilar of autoimmune Enbrel entanercept, in India. Intas says that Intracept cuts...
...of treatment “to about half” compared to Enbrel from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). Intas...
BioCentury | Mar 9, 2015
Company News

Intas Pharmaceuticals sales and marketing update

...Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) markets Neupogen. Intas did not respond to requests for details. Intas...
BioCentury | Dec 22, 2014
Clinical News

Pegfilgrastim regulatory update

...the Biosimilar Price Competition and Innovation Act (BPCIA). Apotex and Intas are co-developing and co-commercializing Intas’...
...are co-developing and co-commercializing Intas’ pegfilgrastim (see BioCentury, Feb. 9, 2009 & May 12, 2008). Intas...
BioCentury | Dec 18, 2014
Company News

FDA will review Apotex's Neulasta biosimilar

...a long-acting treatment for neutropenia in cancer patients. Apotex acquired rights to the biosimilar from Intas...
BioCentury | Aug 4, 2014
Clinical News

Accofil filgrastim regulatory update

...EMA’s CHMP issued a positive opinion recommending approval of an MAA from Intas’ Accord Healthcare Ltd...
...followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. Intas...
BioCentury | Jan 6, 2014
Finance

2014 Financial Markets Preview: Hoping the pause is brief

...Up to Rs3B ($50.6M) Mkt (drug) Q Therapeutics Inc. (OTCBB) 6/20/13 Up to $5M Preclin Intas...
BioCentury | Nov 18, 2013
Finance

Thanksgiving break

...GreTai) (E) 6/25/13 $60-$80M ANDA approved Q Therapeutics Inc. (OTCBB) 6/20/13 Up to $5M Preclin Intas...
BioCentury | Oct 28, 2013
Finance

Hoping to give thanks

...$60-$80M ANDA approved KGI Securities Q Therapeutics Inc. (OTCBB) 6/20/13 Up to $5M Preclin MLV Intas...
BioCentury | Oct 7, 2013
Finance

4Q Financial Markets Preview: Room to grow - for now

...GreTai) (B) 6/25/13 $60-$80M Mkt (drug) Q Therapeutics Inc. (OTCBB) 6/20/13 Up to $5M Preclin Intas...
Items per page:
1 - 10 of 42
BioCentury | Jul 25, 2016
Strategy

Paving the way

...Inc. (NYSE:MRK) Mkt in EU, South Korea Hanwha Chemical Corp. (KSE:009830) Mkt in South Korea Intas...
BioCentury | May 4, 2015
Company News

Intas Pharmaceuticals sales and marketing update

...Intas launched Intacept, a biosimilar of autoimmune Enbrel entanercept, in India. Intas says that Intracept cuts...
...of treatment “to about half” compared to Enbrel from Amgen Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.). Intas...
BioCentury | Mar 9, 2015
Company News

Intas Pharmaceuticals sales and marketing update

...Inc. (NASDAQ:AMGN, Thousand Oaks, Calif.) markets Neupogen. Intas did not respond to requests for details. Intas...
BioCentury | Dec 22, 2014
Clinical News

Pegfilgrastim regulatory update

...the Biosimilar Price Competition and Innovation Act (BPCIA). Apotex and Intas are co-developing and co-commercializing Intas’...
...are co-developing and co-commercializing Intas’ pegfilgrastim (see BioCentury, Feb. 9, 2009 & May 12, 2008). Intas...
BioCentury | Dec 18, 2014
Company News

FDA will review Apotex's Neulasta biosimilar

...a long-acting treatment for neutropenia in cancer patients. Apotex acquired rights to the biosimilar from Intas...
BioCentury | Aug 4, 2014
Clinical News

Accofil filgrastim regulatory update

...EMA’s CHMP issued a positive opinion recommending approval of an MAA from Intas’ Accord Healthcare Ltd...
...followed by bone marrow transplantation considered to be at increased risk of prolonged severe neutropenia. Intas...
BioCentury | Jan 6, 2014
Finance

2014 Financial Markets Preview: Hoping the pause is brief

...Up to Rs3B ($50.6M) Mkt (drug) Q Therapeutics Inc. (OTCBB) 6/20/13 Up to $5M Preclin Intas...
BioCentury | Nov 18, 2013
Finance

Thanksgiving break

...GreTai) (E) 6/25/13 $60-$80M ANDA approved Q Therapeutics Inc. (OTCBB) 6/20/13 Up to $5M Preclin Intas...
BioCentury | Oct 28, 2013
Finance

Hoping to give thanks

...$60-$80M ANDA approved KGI Securities Q Therapeutics Inc. (OTCBB) 6/20/13 Up to $5M Preclin MLV Intas...
BioCentury | Oct 7, 2013
Finance

4Q Financial Markets Preview: Room to grow - for now

...GreTai) (B) 6/25/13 $60-$80M Mkt (drug) Q Therapeutics Inc. (OTCBB) 6/20/13 Up to $5M Preclin Intas...
Items per page:
1 - 10 of 42